Transcriptomics,Genomics

Dataset Information

53

Effect of Imatinib on chronic myelogenous leukemia


ABSTRACT: The Philadelphia chromosome (Ph) encodes the oncogenic BCR-ABL1 tyrosine kinase, which is present in almost every patient with chronic myeloid leukemia. In this study, the tyrosine kinase inhibitor Imatinib was used for pharmacological inhibition of BCR-ABL1. Gene expression profiles of CML cell lines were analyzed in response to Imatinib treatment. Overall design: Three CML cell lines (KU-812, KCL-22, JURL-MK1) were either treated with 10 µM STI571 (Imatinib) for 16 hours or cultured in absence of STI571.

INSTRUMENT(S): [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

SUBMITTER: Markus Müschen  

PROVIDER: GSE24493 | GEO | 2010-10-10

SECONDARY ACCESSION(S): PRJNA132497

REPOSITORIES: GEO

altmetric image

Publications


Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR-ABL1 (ref. 1) and other oncogenic tyrosine kinases. Recent efforts have focused on developing more potent TKIs that also inhibit mutant tyrosine kinases. However, even effective TKIs typically fail to eradicate leukaemia-initiating cells (LICs), which often cause recurrence of leukaemia after initially successful treatment. Here we report the discovery of a novel mechanism of drug resistance, which i  ...[more]

Similar Datasets

2010-09-10 | E-GEOD-23743 | ArrayExpress
2010-09-10 | GSE23743 | GEO
2011-03-01 | E-GEOD-24381 | ArrayExpress
| GSE24381 | GEO
2011-02-15 | E-GEOD-24404 | ArrayExpress
| GSE24404 | GEO
2010-05-27 | E-GEOD-20987 | ArrayExpress
| GSE20987 | GEO
2015-09-15 | E-GEOD-20987 | ExpressionAtlas
2009-12-19 | GSE19567 | GEO